GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the…
Experimental oral therapy GRI-0621 may stabilize lung function in IPF
I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I thought I’d lost. Teaching has always been my passion, the steady flame that keeps…
There will be times when, despite everything you cover in planning for a trip, something happens that you didn’t anticipate. I can guarantee it. I shared with you my vacation details and preparations in my Aug. 26 column, all made to ensure the entire trip would be an opportunity…
Using a specialized lab technique, a collaborative U.S. research team identified cellular changes in the body that could be early drivers of lung scarring (fibrosis) in people with pulmonary fibrosis (PF). That’s according to the findings of a new study in which the researchers, from three universities, exposed lung…
Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by his passion for the foundation’s work. I asked him to share his thoughts…
The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…
First in a series. Shortly after I learned I had idiopathic pulmonary fibrosis (IPF) in January 2017, I came to rely on the Pulmonary Fibrosis Foundation (PFF) as a reliable source of information. That relationship continues today, more than four years after my bilateral lung transplant in…
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring attention to pulmonary fibrosis (PF) — and also interstitial lung diseases (ILDs), which are disorders marked by scarring in the lungs. “We urgently need broader awareness because with it…
“Anticipation, anticipation/ Is makin’ me late/ Is keepin’ me waitin’.” The chorus of Carly Simon’s 1971 song “Anticipation” came to mind earlier this week as my wife, Susan, and I prepare to leave for vacation. Despite booking our trip through the Czech Republic, Germany, and France almost a year…
Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important…
